NZ601018A - Ev576 for use in the treatment of viral infections of the respiratory tract - Google Patents

Ev576 for use in the treatment of viral infections of the respiratory tract

Info

Publication number
NZ601018A
NZ601018A NZ601018A NZ60101811A NZ601018A NZ 601018 A NZ601018 A NZ 601018A NZ 601018 A NZ601018 A NZ 601018A NZ 60101811 A NZ60101811 A NZ 60101811A NZ 601018 A NZ601018 A NZ 601018A
Authority
NZ
New Zealand
Prior art keywords
treatment
respiratory tract
viral infections
sars
influenza
Prior art date
Application number
NZ601018A
Other languages
English (en)
Inventor
Wynne Weston-Davies
Original Assignee
Varleigh Immuno Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1000318.4A external-priority patent/GB201000318D0/en
Priority claimed from GBGB1005071.4A external-priority patent/GB201005071D0/en
Application filed by Varleigh Immuno Pharmaceuticals Ltd filed Critical Varleigh Immuno Pharmaceuticals Ltd
Publication of NZ601018A publication Critical patent/NZ601018A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ601018A 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract NZ601018A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1000318.4A GB201000318D0 (en) 2010-01-08 2010-01-08 Method of treatment
GBGB1005071.4A GB201005071D0 (en) 2010-03-25 2010-03-25 Method of treatment
PCT/GB2011/000022 WO2011083317A1 (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract

Publications (1)

Publication Number Publication Date
NZ601018A true NZ601018A (en) 2013-09-27

Family

ID=44305222

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601018A NZ601018A (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract

Country Status (9)

Country Link
US (4) US20120283167A1 (enExample)
EP (1) EP2521562B1 (enExample)
JP (1) JP5840623B2 (enExample)
CN (1) CN102762223B (enExample)
AU (2) AU2011204483B2 (enExample)
CA (1) CA2785612C (enExample)
NZ (1) NZ601018A (enExample)
PL (1) PL2521562T3 (enExample)
WO (1) WO2011083317A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116785426A (zh) * 2014-03-20 2023-09-22 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
EP4374922A3 (en) 2016-06-14 2024-08-28 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US20220047673A1 (en) * 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
WO2020247610A1 (en) 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN115884764A (zh) * 2020-04-01 2023-03-31 硫创治疗公司 用于治疗乙型冠状病毒感染的半胱胺前体化合物
WO2021226404A1 (en) * 2020-05-08 2021-11-11 Kodiak Sciences Inc. Use of il-6 antibodies and vegf traps, and fusion constructs and conjugates thereof
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3734093A (en) 1992-02-27 1993-09-13 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
MXPA05012880A (es) * 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US7274999B1 (en) * 2006-03-10 2007-09-25 Atmel Corporation Brownout detector system and method
CA2649090A1 (en) * 2006-04-12 2007-10-18 Biocryst Pharmaceuticals, Inc. Intramuscular antiviral treatments
JP2010502687A (ja) * 2006-09-08 2010-01-28 ヴァーレイ・リミテッド 呼吸器疾患の治療方法
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment

Also Published As

Publication number Publication date
US20200155646A1 (en) 2020-05-21
US20120283167A1 (en) 2012-11-08
JP2013516450A (ja) 2013-05-13
AU2016203058B2 (en) 2018-01-18
EP2521562B1 (en) 2019-09-18
PL2521562T3 (pl) 2020-04-30
US20150196619A1 (en) 2015-07-16
AU2011204483A1 (en) 2012-07-12
US9522171B2 (en) 2016-12-20
US20170065677A1 (en) 2017-03-09
JP5840623B2 (ja) 2016-01-06
CA2785612A1 (en) 2011-07-14
AU2016203058A1 (en) 2016-06-02
CN102762223B (zh) 2014-09-03
CN102762223A (zh) 2012-10-31
WO2011083317A1 (en) 2011-07-14
AU2011204483B2 (en) 2016-02-11
EP2521562A1 (en) 2012-11-14
CA2785612C (en) 2019-09-10

Similar Documents

Publication Publication Date Title
NZ601018A (en) Ev576 for use in the treatment of viral infections of the respiratory tract
CY1122292T1 (el) Ενωσεις και μεθοδοι για αντιϊικη αγωγη
MX387277B (es) Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
EA201590813A1 (ru) Катетер для минимизации разбавления дозы во время доставки окиси азота
PH12015500355A1 (en) Compounds for the treatment of paramoxyvirus viral infections
PT2435025T (pt) Administração, por via respiratória, de agentes activos
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
EP2720742A4 (en) MEDICAL INHALATION DEVICES AND VALVES THEREFOR AND COMPONENTS THEREOF
ES2531367T3 (es) Composición antivírica sinérgica y uso de la misma
WO2012112489A3 (en) Compositions and methods for the therapy and diagnosis of influenza
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
EA201290897A1 (ru) Вакцины для пандемического гриппа
EA201400235A1 (ru) Вакцины против гриппа на основе н5
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
BR112014028632A8 (pt) Composto, composição farmacêutica, e, método para preparar um composto
EP3017816A4 (en) DIINDOLYLMETHANE-BASED MEDICAMENT AND USE THEREOF FOR THE TREATMENT OF INFLUENZA AND VIRAL AIRWAY INFECTIONS
EA201370058A1 (ru) Средство против вируса гриппа b
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais

Legal Events

Date Code Title Description
PSEA Patent sealed
ASS Change of ownership

Owner name: VOLUTION IMMUNO PHARMACEUTICALS SA, CH

Effective date: 20140814

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2016 BY CPA GLOBAL

Effective date: 20141204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2017 BY CPA GLOBAL

Effective date: 20151204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2018 BY CPA GLOBAL

Effective date: 20161202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2019 BY CPA GLOBAL

Effective date: 20171130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2020 BY CPA GLOBAL

Effective date: 20181129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2021 BY CPA GLOBAL

Effective date: 20191128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2022 BY CPA GLOBAL

Effective date: 20201203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2023 BY CPA GLOBAL

Effective date: 20211202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2024 BY CPA GLOBAL

Effective date: 20221202

LAPS Patent lapsed